Anthony B. Evnin, Director at Juno Therapeutics, Inc. (JUNO), bought 16,000 shares at $36.94 ($585K) on 2016-03-28, disclosed to the SEC on 2016-03-30.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $36.22 | 3,946 | $143K | 24.4% |
| 2 | $36.22 | 3,946 | $143K | 24.4% |
| 3 | $36.94 | 4,054 | $150K | 25.6% |
| 4 | $36.94 | 4,054 | $150K | 25.6% |
| Total | $36.58 avg | 16,000 | $585K | 100% |
| Filing → |
| CNST | BUY | 2019-10-04 | $48.0M | — | Filing → |
| AVEO | BUY | 2018-11-26 | $223 | — | Filing → |
| AVEO | SELL | 2018-11-16 | $4.3M | — | Filing → |